CPT® Code 0539T

Deleted

Chimeric antigen receptor T-cell (CAR-T) therapy represents a groundbreaking approach in the field of immunotherapy, utilizing the patient's own immune cells, specifically lymphocytic T-cells, to combat cancer. This innovative treatment involves a sophisticated process where T-cells are extracted from the patient's blood and genetically modified in a laboratory setting. The modification is achieved through the introduction of a disarmed virus that carries genetic material designed to instruct the T-cells to produce chimeric antigen receptors (CARs) on their surfaces. These CARs are crucial as they enable the T-cells to identify and bind to specific protein antigens present on the surface of cancer cells, thereby facilitating targeted destruction of these malignant cells. The procedure begins with the withdrawal of blood from the patient, which may take place over several days, followed by the separation of T-lymphocytes from the blood. Once isolated, these T-lymphocytes undergo genetic engineering to create CAR-T cells, which are then expanded in number to reach hundreds of millions. Concurrently, the patient receives lymphocytic cell-depleting chemotherapy to prepare their immune system for the subsequent infusion of the modified T-cells. After the CAR-T cells are fully prepared, they are reintroduced into the patient's body, where they actively seek out and eliminate cancer cells. The persistence of CAR-T cells in the body is a significant advantage, as they can continue to recognize and attack any remaining cancer cells, thereby reducing the risk of cancer recurrence.